THE PEER-REVIEWED FORUM FOR EVIDENCE IN BENEFIT DESIGN ™ JULY/AUGUST 2012
VOLUME 5, NUMBER 5
FOR PAYERS, PURCHASERS, POLICYMAKERS, AND OTHER HEALTHCARE STAKEHOLDERS
EDITORIAL
“SCOTUS Redux” David B. Nash, MD, MBA COMMENTARY
Healthcare Reform After SCOTUS: Hard Decisions Needed to Avoid Health Sector Meltdown Joseph R. Antos, PhD ™
BUSINESS
Curbing the Costly Trend: Exploring the Need for a Progressive Approach to the Management of Specialty Pharmaceuticals Under the Medical Benefit Michael S. Jacobs, RPh; Kjel A. Johnson, PharmD, BCPS, FCCP, FAMCP Stakeholder Perspective by James T. Kenney, Jr, RPh, MBA CLINICAL
Anticoagulant Use for Prevention of Stroke in a Commercial Population with Atrial Fibrillation Aarti A. Patel, PharmD, MBA; Barb Lennert, RN, BSN, MAOM; Brian Macomson, PharmD; Winnie W. Nelson, PharmD; Gary M. Owens, MD; Samir H. Mody, PharmD, MBA; Jeff Schein, DrPH, MPH Stakeholder Perspective by Jack E. Fincham, PhD, RPh
Conceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized Medicine Demissie Alemayehu, PhD; Joseph C. Cappelleri, PhD, MPH Stakeholder Perspective by Michael F. Murphy, MD, PhD INDUSTRY TRENDS
Cost Management through Care Management: A Perspective on Choosing the Right Specialty Pharmacy Partner, PART 1 Michael Einodshofer, RPh, MBA; Stephen Kansler
©2012 Engage Healthcare Communications, LLC www.AHDBonline.com